Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer
- Authors
- Oh, Sumin; Ko, Je Yeong; Oh, Chaeun; Yoo, Kyung Hyun
- Issue Date
- Dec-2017
- Publisher
- Springer New York LLC
- Keywords
- Epigenetic regulation; DNMT inhibitors; HDAC inhibitors; Therapeutic targets; Breast cancer
- Citation
- Advances in Experimental Medicine and Biology, v.1026, pp 287 - 313
- Pages
- 27
- Journal Title
- Advances in Experimental Medicine and Biology
- Volume
- 1026
- Start Page
- 287
- End Page
- 313
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/5026
- DOI
- 10.1007/978-981-10-6020-5_14
- ISSN
- 0065-2598
2214-8019
- Abstract
- Breast cancer is one of complex diseases that are influenced by environment. Various genetic and epigenetic alterations are provoking causes of breast carcinogenesis. Dynamic epigenetic regulation including DNA methylation and histone modification induces dysregulation of genes related to proliferation, apoptosis, and metastasis in breast cancer. DNA methylation is strongly associated with the repression of transcription through adding to the methyl group by DNA methyltransferases (DNMTs), and tumor suppressor genes such as CCND2 and RUNX3 have been investigated to undergo hypermethylation at promoter region in breast cancer. In addition, histone deacetylases (HDACs) contribute to transcriptional repression by removing acetyl group at lysine residues leading to tumorigenesis. Since epigenetic changes are reversible, therapeutic approaches have been applied with epigenetic modification drugs such as DNMT inhibitors and HDAC inhibitors. In this chapter, we will summarize the feature of epigenetic markers in breast cancer cells and the effect of single or combination of epigenetic reagents for breast cancer therapy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 이과대학 > 생명시스템학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.